Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Arbutus Biopharma ( (ABUS) ).
Michael J. Sofia is set to retire as the Chief Scientific Officer of Arbutus Biopharma, Inc. by the end of 2024, and an amendment to his employment agreement has been made regarding his retirement benefits and post-retirement activities. The amendment ensures that Dr. Sofia will receive his annual bonus for 2024 and clarifies the scope of activities he can engage in after retirement, in line with his non-compete obligations.
See more insights into ABUS stock on TipRanks’ Stock Analysis page.